Back to Market返回行情

AMRX Amneal Pharmaceuticals, Inc.

USHealthcare
$16.96-0.53%ClosedMarket Cap: $5.42B

As of 2026-07-08 16:00

Why AMRX matters now

Amneal Pharmaceuticals, Inc. (AMRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.96 with -0.53% on the session and $5.42B in market capitalization; recent performance reads 1-month +37.26% and YTD +28.65%.

The latest financial table shown here is Q1 2026, with revenue of $722.5M, net income of $62.5M, and EPS of $0.19. Investors can compare that operating picture with valuation signals such as P/E 54.75 and FCF yield 4.0%.

The latest indexable market news headline is "Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Autor Deborah M. filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

54.75

PEG

0.34

P/B

-117.42

P/S

1.70

EV/EBITDA

12.25

DCF Value

$15.22

FCF Yield

4.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

38.7%

Operating Margin

11.8%

Net Margin

4.0%

ROE

-144.7%

ROA

3.5%

ROIC

12.6%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$722.5M$62.5M$0.19
Q4 2025$814.3M$35.1M$0.11
FY 2025$3.02B$72.1M$0.22
Q3 2025$784.5M$2.4M$0.01

Analyst Ratings

Consensus

Buy

Target (Consensus)

$17.33

Target (Median)

$17.00

Target Range

$16.00 - $19.00

Strong Buy: 2Buy: 3Hold: 0Sell: 0Strong Sell: 0
BarclaysOverweight
2026-05-20
Truist SecuritiesBuy
2026-03-02
Piper SandlerOverweight
2025-10-31
JP MorganOverweight
2025-09-16

Trading Activity

Insider Trades

Autor Deborah M.director
Sell2026-05-12
Yanai Shlomodirector
Sell2026-05-08
Yanai Shlomodirector
Sell2026-05-08
MEISTER PAUL Mdirector
Sell2026-05-08
MEISTER PAUL Mdirector
Sell2026-05-08

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

US

Exchange

Beta

1.32

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.